Sunil ShahCEO at o2h Group
Sunil Shah is the CEO of the o2h Group which has developed an engine for seeding a pipeline of early
stage life science assets through research collaborations, in-licensing, spin-outs & investments. The DNA
of o2h is centred around the nurturing of its people, values and culture, it reflects in the way we work with
each other, as well as our collaborators and partners. In 2019, Sunil won the UKBAA Angel Investor of
the Year Award as well as the OBN Special Recognition Award for his contribution to the life sciences
industry in the UK.
Sunil is a Board Director of Cambridge Angels and also is a member of the Advisory Panel of Cancer
Research UK (CRUK) which is the UK’s largest cancer research charity. He is also a non-executive
director in the Board of Bioindustry Association Ltd. (BIA). He is either Chairman, Director, Board
Observer or investor of: Phoremost, Exonate, Opal Oncology, Five Alarm Bio, Somaserve, DeepMatter,
Oppilotech, Sentinel, Small Pharma, Arecor, Metrion, Talisman, Stemnovate, Acacia, Privitar and Oxford
Drug Design. Sunil has a degree in Biochemistry and an MBA from Cambridge University.